Sensitive and specific LC-ESI-MS/MS method for the determination of a styrylquinoline, BA011FZ041, a potent HIV anti-integrase agent, in rat plasma.
A LC-MS/MS method was validated for the determination of BA011FZ041, a styrylquinoline derivative. After addition of BA011FZ055 as internal standard (IS), the method involved solid phase extraction (SPE), LC separation with an ether-phenyl column and quantification by MS/MS after positive ESI. The calibration curve, ranging from 1 to 500 ng/mL was fitted to a 1/x-weighted quadratic regression model. Lower limit of quantification (LLOQ) was 1 ng/mL using 100 microL of plasma. Intra- and inter-assay precision and accuracy values were within the regulatory limits. The method was successfully applied to the determination of BA011FZ041 in rat plasma and PBMCs after i.v. dosing.
Pruvost
Alain
A
CEA, Service de Pharmacologie et d'Immunologie, DSV/DRM, CEA/Saclay, 91191 Gif-sur-Yvette Cedex, France. alain.pruvost@cea.fr
Levi
Mikaël
M
Zouhiri
Fatima
F
Ménier
Isabelle
I
Benech
Henri
H
D000818:Animals; D002853:Chromatography, Liquid / Q000379:methods*; D019428:HIV Integrase Inhibitors / Q000097:blood*; D008297:Male; D011804:Quinolines / Q000097:blood*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods*
C521224:BA011FZ041; D019428:HIV Integrase Inhibitors; D011804:Quinolines